Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Harvey, P. D. Articles by Davidson, M. Search for Related Content PubMed Citation Articles by Harvey, P. D. Articles by Davidson, M. Schizophrenia Spectrum Disorders Atypical Neuroleptics Conventional Neuroleptics Cognition

Treatment of Cognitive Impairment in Early Psychosis: A Comparison of Risperidone and Haloperidol in a Large Long-Term Trial

OBJECTIVE: Cognitive impairment is a major determinant of functional outcome in schizophrenia. Treatment of cognitive impairment at the time of the first episode may have the potential to change functional outcomes of the illness. This study examined changes associated with treatment with risperidone compared with haloperidol in aspects of cognitive functioning known to be associated with functional outcomes. The study was conducted in a large group of patients experiencing their first episode of schizophrenia. METHOD: Cognitive assessments were conducted in 533 patients experiencing their first episode of schizophrenia or a related psychosis who had been randomly assigned to receive low doses of risperidone or haloperidol. The cognitive assessments were repeated at several different follow-up intervals; 359 patients were reexamined at the 3-month follow-up. The assessments included examinations of verbal and visuospatial episodic memory, vigilance, executive functioning, processing speed, and verbal fluency. Patients’ clinical symptoms were also rated with the Positive and Negative Syndrome Scale. RESULTS: Improvements from baseline were found in the risperidone-treated patients for episodic memory, verbal fluency, vigilance, executive functioning, and visuomotor speed. Haloperidol-treated patients also showed improvements from baseline in episodic memory, vigilance, and visuomotor speed but not in executive functioning or verbal fluency. Comparison of differential treatment effects on a composite measure of cognitive functioning found that risperidone was significantly more beneficial than haloperidol after 3 months of treatment. Changes in Positive and Negative Syndrome Scale scores were correlated overall with improvement in the haloperidol-treated patients but not in the risperidone-treated patients. CONCLUSIONS: Treatment with risperidone at the time of the first episode of schizophrenia is associated with wide-ranging improvements in cognitive functioning. Overall improvement is significantly greater with risperidone than with haloperidol. Further, cognitive improvement associated with treatment with risperidone was not influenced by changes in symptoms, but that relationship was significant in haloperidol-treated patients.

This article has been cited by other articles:

				A. B. Hains and A. F.T. Arnsten Molecular mechanisms of stress-induced prefrontal cortical impairment: Implications for mental illness Learn. Mem., August 6, 2008; 15(8): 551 - 564. [Abstract] [Full Text] [PDF]

				R. S. E. Keefe and P. D. Harvey Implementation Considerations for Multisite Clinical Trials with Cognitive Neuroscience Tasks Schizophr Bull, July 1, 2008; 34(4): 656 - 663. [Abstract] [Full Text] [PDF]

				S. K. Hill, J. L. Reilly, M. S. H. Harris, T. Khine, and J. A. Sweeney Oculomotor and Neuropsychological Effects of Antipsychotic Treatment for Schizophrenia Schizophr Bull, May 1, 2008; 34(3): 494 - 506. [Abstract] [Full Text] [PDF]

				J. O. Brooks and J. C. Hoblyn Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults J Geriatr Psychiatry Neurol, December 1, 2007; 20(4): 199 - 214. [Abstract] [PDF]

				R. S.E. KEEFE, J. A. SWEENEY, H. GU, R. M. HAMER, D. O. PERKINS, J. P. McEVOY, and J. A. LIEBERMAN Dr. Keefe and Colleagues Reply Am J Psychiatry, December 1, 2007; 164(12): 1911 - 1912. [Full Text] [PDF]

				T. E. Goldberg, R. S. Goldman, K. E. Burdick, A. K. Malhotra, T. Lencz, R. C. Patel, M. G. Woerner, N. R. Schooler, J. M. Kane, and D. G. Robinson Cognitive Improvement After Treatment With Second-Generation Antipsychotic Medications in First-Episode Schizophrenia: Is It a Practice Effect? Arch Gen Psychiatry, October 1, 2007; 64(10): 1115 - 1122. [Abstract] [Full Text] [PDF]

				R. S.E. Keefe, J. A. Sweeney, H. Gu, R. M. Hamer, D. O. Perkins, J. P. McEvoy, and J. A. Lieberman Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison Am J Psychiatry, July 1, 2007; 164(7): 1061 - 1071. [Abstract] [Full Text] [PDF]

				S. K. Erickson, J. R. Ciccone, S. B. Schwarzkopf, J. S. Lamberti, and M. J. Vitacco Legal Fallacies of Antipsychotic Drugs J Am Acad Psychiatry Law, June 1, 2007; 35(2): 235 - 246. [Abstract] [Full Text] [PDF]

				R. S. E. Keefe, R. M. Bilder, S. M. Davis, P. D. Harvey, B. W. Palmer, J. M. Gold, H. Y. Meltzer, M. F. Green, G. Capuano, T. S. Stroup, et al. Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial Arch Gen Psychiatry, June 1, 2007; 64(6): 633 - 647. [Abstract] [Full Text] [PDF]

				J. Rabinowitz, P. D. Harvey, M. Eerdekens, and M. Davidson Premorbid functioning and treatment response in recent-onset schizophrenia The British Journal of Psychiatry, July 1, 2006; 189(1): 31 - 35. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us